ERBB3 and neoplasm: It has been discovered that HER3 blockade inhibited HER3-PI3K-AKT-mTOR oncogenic signaling and simultaneously reversed the immunosuppressive tumor microenvironment, demonstrating that co-targeting HER3 and PD-1 led to tumor growth inhibition and subsequently enhanced therapeutic immune responses (57).